
XOMA (XOMA) Stock Forecast & Price Target
XOMA (XOMA) Analyst Ratings
Bulls say
XOMA Royalty Corp is positioned for substantial revenue growth, with anticipated annual increases of over 20% through 2026, attributed to rising commercial sales from key products such as Vabysmo and new launches like Ojemda and Miplyffa. The company's total income from royalty agreements surged to $28.5 million in 2024, reflecting a significant leap from the $4.8 million recorded in 2023, bolstered by higher revenue from customer contracts and purchased receivables. Looking ahead, XOMA is projected to generate $49.0 million in revenues for 2026, with potential contributions from earlier-stage assets and milestone payments, further solidifying its positive financial outlook.
Bears say
XOMA Royalty Corp has experienced significant revenue and net earnings variability, primarily due to fluctuations in the international market for its products, which poses risks in light of potential economic downturns and changes in governmental policies. The company's operations could be adversely affected by factors such as failed clinical trials or inadequate funding for drug development, leading to heightened stock volatility. Additionally, XOMA's recent share price declines, following earlier gains, reflect broader market trends in the biotechnology sector, which could be further impacted by the departure of key executives with critical industry knowledge.
This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.
XOMA (XOMA) Analyst Forecast & Price Prediction
Start investing in XOMA (XOMA)
Order type
Buy in
Order amount
Est. shares
0 shares